Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Gross Margin data on record, last reported at 88.78% in Q3 2025.

  • For Q3 2025, Gross Margin rose 53550.0% year-over-year to 88.78%; the TTM value through Sep 2025 reached 28.19%, down 3918.0%, while the annual FY2024 figure was 5.43%, 327.0% down from the prior year.
  • Gross Margin reached 88.78% in Q3 2025 per BTAI's latest filing, up from 10.83% in the prior quarter.
  • Across five years, Gross Margin topped out at 95.63% in Q1 2023 and bottomed at 446.73% in Q3 2024.
  • Average Gross Margin over 3 years is 13.84%, with a median of 86.25% recorded in 2024.
  • Peak YoY movement for Gross Margin: plummeted -39658bps in 2024, then soared 53550bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 89.89% in 2023, then tumbled by -42bps to 127.32% in 2024, then surged by 170bps to 88.78% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 88.78% in Q3 2025, 10.83% in Q2 2025, and 91.67% in Q1 2025.